Murashita T, Yasuda K
Department of Cardiovascular Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
Nihon Kyobu Geka Gakkai Zasshi. 1996 Nov;44(11):2019-26.
Many studies suggest that single-dose and multidose cardioplegia are protective in the ischemic adult heart, but in the neonatal heart single-dose cardioplegia is only protective, whereas multidose cardioplegia is damaging. We examined three clinically used cardioplegic solutions to compare the protective properties of single-dose and multidose cardioplegia in the neonatal rabbit heart (aged 7 to 10 days). The clinical solution studied were St. Thomas', Typers' and Bretschneider's solutions. In isolated working hearts (n = 8/group), cardiac function was assessed prior to 10 hours of ischemia (20 degrees C) and again after 35 min reperfusion (15 min Langendorff, 20 min working). All hearts received a pre-ischemic infusion (10 ml) of cardioplegic solution. The cardioplegic solution was given either as a single infusion (single-dose) or as repeated infusions (multidose) with 5 ml of cardioplegic solution every hour. The changes in coronary vascular resistance (CVR) during repeated cardioplegic infusions were measured in the multidose groups. During 15 min of Langendorff reperfusion, creatine kinase (CK) leakage and CVR were evaluated in all hearts. The results revealed that single-dose cardioplegia provided significantly better functional recovery than multidose cardioplegia in hearts given St. Thomas' or Tyers' solutions, while using Bretschneider solution single-dose cardioplegia Tended to provide better functional recovery. Post-ischemic CK leakages were higher in hearts given Bretschneider's solution in both single-dose and multidose cardioplegia. In hearts given St. Thomas' and Tyers' solutions, post-ischemic CVR in the single-dose group is lower than that in the multidose group, whereas post-ischemic CVR was lowest in the multidose group using Bretschneider's solution. Among multidose groups, CVR prior to reperfusion was lowest in Breschneider's solution as well. In conclusions, these results confirmed that, using the clinical solutions studied, single-dose cardioplegia provided better functional recovery than multidose cardioplegia in the neonatal rabbit heart. However, low CVR in Bretschenider's multidose cardioplegia suggested the better protection in coronary vasculature although functional recovery was poor.
许多研究表明,单剂量和多剂量心脏停搏液对成年缺血心脏具有保护作用,但在新生心脏中,单剂量心脏停搏液仅具有保护作用,而多剂量心脏停搏液则具有损害作用。我们研究了三种临床使用的心脏停搏液,以比较单剂量和多剂量心脏停搏液对新生兔心脏(7至10日龄)的保护特性。所研究的临床溶液为圣托马斯液、泰尔斯液和布雷施奈德液。在离体工作心脏(每组n = 8)中,在缺血10小时(20℃)前评估心脏功能,并在再灌注35分钟后(15分钟Langendorff灌注,20分钟工作)再次评估。所有心脏均接受一次缺血前心脏停搏液输注(10 ml)。心脏停搏液以单次输注(单剂量)或每小时重复输注5 ml心脏停搏液(多剂量)的方式给予。在多剂量组中测量重复输注心脏停搏液期间冠状动脉血管阻力(CVR)的变化。在15分钟的Langendorff再灌注期间,评估所有心脏的肌酸激酶(CK)泄漏和CVR。结果显示,在给予圣托马斯液或泰尔斯液的心脏中,单剂量心脏停搏液比多剂量心脏停搏液能提供显著更好的功能恢复,而使用布雷施奈德液时,单剂量心脏停搏液倾向于提供更好的功能恢复。在单剂量和多剂量心脏停搏液中,给予布雷施奈德液的心脏缺血后CK泄漏更高。在给予圣托马斯液和泰尔斯液的心脏中,单剂量组缺血后的CVR低于多剂量组,而使用布雷施奈德液的多剂量组缺血后CVR最低。在多剂量组中,再灌注前布雷施奈德液组的CVR也最低。总之,这些结果证实,在所研究的临床溶液中,单剂量心脏停搏液比多剂量心脏停搏液能为新生兔心脏提供更好的功能恢复。然而,布雷施奈德多剂量心脏停搏液中较低的CVR表明,尽管功能恢复较差,但对冠状动脉血管的保护更好。